SIBN icon

SI-BONE Inc

17.84 USD
-0.16
0.89%
At close Feb 21, 4:00 PM EST
After hours
17.84
+0.00
0.00%
1 day
-0.89%
5 days
8.45%
1 month
3.18%
3 months
45.16%
6 months
18.22%
Year to date
28.07%
1 year
-12.07%
5 years
-10.62%
10 years
-11.07%
 

About: SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Employees: 344

0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

76% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 17

21% more call options, than puts

Call options by funds: $4.29M | Put options by funds: $3.55M

11% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 45

7% more funds holding

Funds holding: 133 [Q3] → 142 (+9) [Q4]

6% less capital invested

Capital invested by funds: $572M [Q3] → $539M (-$32.9M) [Q4]

6.48% less ownership

Funds ownership: 98.09% [Q3] → 91.61% (-6.48%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$19
7%
upside
Avg. target
$19
7%
upside
High target
$19
7%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Needham
David Saxon
37% 1-year accuracy
24 / 65 met price target
7%upside
$19
Buy
Reiterated
13 Jan 2025

Financial journalist opinion

Based on 3 articles about SIBN published over the past 30 days

Neutral
Business Wire
1 day ago
Bruker Appoints Laura Francis to its Board of Directors
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (Nasdaq: SIBN), a medical device company s.
Bruker Appoints Laura Francis to its Board of Directors
Positive
Zacks Investment Research
4 days ago
Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy?
Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy?
Neutral
GlobeNewsWire
2 weeks ago
SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025
SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.71%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 64.7% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.71%: Here's is How to Trade
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts See an 83.56% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
The consensus price target hints at an 83.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See an 83.56% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
Neutral
GlobeNewsWire
3 months ago
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
Neutral
Seeking Alpha
3 months ago
SI-BONE, Inc. (SIBN) Q3 2024 Earnings Call Transcript
SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - BofA Securities Young Li - Jefferies Drew Ranieri - Morgan Stanley Caitlin Cronin - Canaccord Richard Newitter - Truist Securities Operator Good afternoon, and welcome to SI-BONE's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
SI-BONE, Inc. (SIBN) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago.
Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
3 months ago
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance
SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024.
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance
Neutral
GlobeNewsWire
3 months ago
SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™
The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion procedures The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion procedures
SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™
Charts implemented using Lightweight Charts™